A common yeast fiber reshaped bone-marrow immunity in obese mice

A new study in Cell Reports00726-6) shows that beta-glucan, a fiber found in yeast and already sold as a dietary supplement, partially reversed an obesity-driven decline in cancer-fighting immune cells in mice. The work comes from a joint team at Trinity College Dublin and University College Dublin, and is described by the researchers as the first peer-reviewed evidence that a dietary supplement can train the bone-marrow progenitors that seed the body's immune system, an effect they call trained hematopoiesis.

The mice in the study were obese, fed either standard or high-fat diets and given beta-glucan for 4 to 12 weeks before being challenged with cancer cells. The effect was specific to those conditions. The team tested three tumor types, colorectal, skin, and breast, and tracked whether the supplement could rescue anti-tumor immunity after the animals lost weight.

Beta-glucan is a soluble fiber found in the cell walls of baker's yeast, oats, barley, and mushrooms. It has been sold over the counter as an immune-support supplement for decades, with human evidence on post-surgical infection and seasonal cold duration mixed and modest. The Dublin study does not relitigate that human record. It tests a specific molecular mechanism in a specific disease model: obese mice, three cancer cell lines.

Obesity already raises the risk of several cancer types in humans, and one mechanism behind that risk is the immune system: obesity can blunt how tumor-killing immune cells develop and respond. The Dublin team wanted to know whether a dietary intervention could push back at the cellular source.

The answer, in obese mice, is partial. Beta-glucan reprogrammed early-stage immune cells in the bone marrow, the progenitors that give rise to macrophages and other first-responder cells. Those reprogrammed cells produced stronger, longer-lasting anti-tumor responses when the mice were later exposed to cancer cells, and the protective effect persisted after the animals returned to a normal weight, the team reports in the paper00726-6).

The joint institutional release from Trinity and UCD and the aggregator coverage on ScienceDaily frame the result as a step toward nutrition-trained immunity, the idea that specific foods or fibers can deliberately tune the immune system the way a vaccine tunes it against a pathogen.

What the data does not yet support is a human recommendation. The work is preclinical, restricted to obese mice, and tested against three tumor types only. Lean mice, human doses, and which cancers respond in people are all open questions, and the paper itself does not claim otherwise.

Lead author Anna Ledwith, a postdoc, and senior authors Frederick Sheedy at Trinity and Helen Roche at UCD framed the finding as a mechanism, not a therapy. The next step the team names is whether the same bone-marrow reprogramming holds in lean animals, in human immune cells, and against which cancers.

The cellular address, bone-marrow progenitors, is what makes this paper different. Most prior work on trained immunity has focused on mature immune cells already circulating in blood or stationed in tissues. The Dublin result points upstream, at the source.

For now, the practical question of whether someone with obesity should take beta-glucan to lower their cancer risk has no clinical answer. The mouse data opens a mechanism, not a recommendation.